[Diagnosis and therapy for systemic sclerosis].
Hisanori
H
Umehara
Masao
M
Tanaka
Yasufumi
Y
Masaki
Toshihiro
T
Fukushima
D001323:Autoantibodies; D002503:Centromere / Q000276:immunology; D004264:DNA Topoisomerases, Type I / Q000276:immunology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D006976:Hypertension, Pulmonary / Q000209:etiology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008286:Malabsorption Syndromes / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000209:etiology; D012017:Referral and Consultation; D012595:Scleroderma, Systemic / Q000150:complications / Q000175:diagnosis* / Q000276:immunology / Q000503:physiopathology / Q000628:therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D001323:Autoantibodies; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D004264:DNA Topoisomerases, Type I